COMPARISON OF BACTERIAL PROBIOTICS (BIFIDOBACTERIUM AND LACTOBACILLUS) VERSUS FUNGAL PROBIOTICS (SACCHAROMYCES) IN TREATING ACUTE DIARRHEA IN CHILDREN AGED 6 MONTHS TO 5 YEARS
DOI:
https://doi.org/10.55519/JAMC-03-13464Keywords:
Acute Watery Diarrhea, “Bacterial Probiotics (Bifidobacterium and Lactobacillus), Fungal Probiotics (Saccharomyces),” Non-Randomized Control Trial.Abstract
Background: Acute diarrhoea among children mainly due to infection must be treated prophylactically to reduce mortality. The objective of this study was to compare the outcome of using bacterial probiotics (Bifidobacterium and Lactobacillus) versus fungal probiotics (Saccharomyces) for acute diarrhoea among children aged 6 months to 5 years. Methods: A non-randomized control trial was conducted at diarrhoea ward, the Children’s Hospital, Lahore from 1st March 2022 to 1st March 2024. 200 children were recruited in the study using non-probability consecutive sampling technique which were divided equally into two groups receiving either bacterial probiotics or fungal probiotics. The children were followed up till resolution of diarrhoea. Diarrhoeal duration and stool frequency were noted. Data was entered and analysed using SPSS Version 26. Results: Out of 200 children, 52.5% were male and 47.5% were female. Mean age of the sample was 2.24±1.54 years, mean baseline and follow up diarrhoea duration was 3.52±1.44 and 3.47±1.25 days and stool frequency at follow up was 3.75±1.15. Complete diarrhoeal resolution was seen among 95% of the children using bacterial probiotics while 87% of the children using fungal probiotics (p=0.048). Regarding diarrhoeal duration (days) among the two groups, the mean was 3.11±1.36 (bacterial probiotic group) and 3.88±1.02 (fungal probiotic group) (p<0.001) and regarding stool frequency, the mean was 2.97±0.55 (bacterial probiotic group) and 4.57±1.07 (fungal probiotic group) (p<0.001). Conclusion: It can be concluded from this study that diarrhoeal resolution along with stool frequency was better among children using bacterial probiotics as compared to those using fungal probiotics.References
Demissie GD, Yeshaw Y, Aleminew W, Akalu Y. Diarrhoea and associated factors among under five children in sub-Saharan Africa: evidence from demographic and health surveys of 34 sub-Saharan countries. PLoS One 2021;16(9):e0257522.
Reiner Jr RC, Graetz N, Casey DC, Troeger C, Garcia GM, Mosser JF, et al. Variation in childhood diarrhoeal morbidity and mortality in Africa, 2000–2015. N Engl J Med 2018;379(12):1128–38.
Mantegazza C, Molinari P, D’Auria E, Sonnino M, Morelli L, Zuccotti GV. Probiotics and antibiotic-associated diarrhoea in children: A review and new evidence on Lactobacillus rhamnosus GG during and after antibiotic treatment. Pharmacol Res 2018;128:63–72.
Sharif MR, Kashani HH, Ardakani AT, Kheirkhah D, Tabatabaei F, Sharif A. The effect of a yeast probiotic on acute diarrhoea in children. Probiotics Antimicrob Proteins 2016;8:211–4.
Yang B, Lu P, Li MX, Cai XL, Xiong WY, Hou HJ, et al. A meta-analysis of the effects of probiotics and synbiotics in children with acute diarrhoea. Medicine 2019;98(37):e16618.
Bron PA, Kleerebezem M, Brummer RJ, Cani PD, Mercenier A, MacDonald TT, et al. Can probiotics modulate human disease by impacting intestinal barrier function? Br J Nutr 2017;117(1):93–107.
Bhat S, Shreekrishna GN, Savio CD. Efficacy of probiotics in acute diarrhoea in children. Int J Contemp Pediatr 2018;5(4):1646–50.
Khan NA, Munir SS. To determine outcome of probiotics in treatment of acute diarrhoea in children. Pak J Med Health Sci 2021;15(8):1829–31.
Li R, Lai Y, Feng C, Dev R, Wang Y, Hao Y. Diarrhoea in under five year-old children in Nepal: a spatiotemporal analysis based on demographic and health survey data. Int J Environ Res Public Health 2020;17(6):e2140.
Iqbal Z, Ahmed S, Tabassum N, Bhattacharya R, Bose D. Role of probiotics in prevention and treatment of enteric infections: A comprehensive review. Biotech 2021;11(5):242.
Li YT, Xu H, Ye JZ, Wu WR, Shi D, Fang DQ, et al. Efficacy of Lactobacillus rhamnosus GG in treatment of acute pediatric diarrhoea: A systematic review with meta-analysis. World J Gastroenterol 2019;25(33):4999–5016.
Awais M, Alam S, Wali N, Mehmood R, Nasir U, Waheed A. Comparison of the Clinical Efficacy of Bacteria-Based Probiotics to Fungi-Based Probiotics. J Sharif Med Dental Coll Lahore 2021;7(1):21–4.
Shati AA, Khalil SN, Asiri KA, Alshehri AA, Deajim YA, Al-Amer MS, et al. Occurrence of diarrhoea and feeding practices among children below two years of age in southwestern Saudi Arabia. Int JEnviron Res Public Health 2020;17(3):e722.
Stier H, Bischoff SC. Saccharomyces boulardii CNCM I-745 influences the gut-associated immune system. MMW Fortschr Med 2017;159(Suppl 5):1–6.
Sanyaolu A, Okorie C, Marinkovic A, Jaferi U, Prakash S, Jan A, et al. Global epidemiology and management of acute diarrhoea in children from developing countries. Ann Pediatr Child Health 2020;8(8):1205.
Mahmud I, Das S, Khan SH, Faruque AS, Ahmed T. Gender disparity in care-seeking behaviours and treatment outcomes for dehydrating diarrhoea among under-5 children admitted to a diarrhoeal disease hospital in Bangladesh: an analysis of hospital-based surveillance data. BMJ Open 2020;10(9):e038730.
Malagón-Rojas JN, Mantziari A, Salminen S, Szajewska H. Postbiotics for preventing and treating common infectious diseases in children: a systematic review. Nutrients 2020;12(2):389.
Dinleyici EC, Kara A, Dalgic N, Kurugol Z, Arica V, Metin O, et al. Saccharomyces boulardii CNCM I-745 reduces the duration of diarrhoea, length of emergency care and hospital stay in children with acute diarrhoea. Benef Microbes 2015;6(4):415–21.
Guarino A, Guandalini S, Vecchio AL. Probiotics for prevention and treatment of diarrhoea. J Clin Gastroenterol 2015;49:S37–45.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Safar Ali Shah , Samia Naz , Fazaila Jabeen, Muhammad Adnan Rashid, Abdul Rahman, Zeeshan Khan
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
